For example, a minority discussed the considerable uncertainty around secondary findings (e.g., what a BRCA1 pathogenic variant would mean in the absence of a personal/family history of cancer), or that participants could opt in or opt out if they later changed their minds. The gene discussed is BRCA1; the disease is cancer.